Loading...
•
Sep 30, 2024
Immunocore Q3 2024 Earnings Report
Revenue increased driven by higher demand in the United States and Germany, and EPS increased compared to the same period in the previous year.
Key Takeaways
Immunocore reported a strong third quarter with KIMMTRAK net revenues of $80.2 million, a 28% increase over 3Q 2023. The company also reported positive net income and advanced its pipeline with ongoing Phase 3 trials and presentations of clinical data.
KIMMTRAK net revenues reached $80.2 million, demonstrating 28% growth compared to 3Q 2023.
Phase 3 trials for cutaneous melanoma (PRISM-MEL-301 and TEBE-AM) are ongoing, and the Phase 3 trial in adjuvant uveal melanoma (ATOM) is set to begin randomization in 4Q 2024.
Phase 1 brenetafusp data in platinum-resistant ovarian cancer patients was presented.
Earnings per share (EPS) for 3Q 2024 was $0.17, compared to $0.02 in 3Q 2023.
Revenue by Geographic Location
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...